13 completed, 7 terminated, 1 withdrawn. 10 Phase 1, 10 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 8, Terminated 2 |
| Phase 2 | 10 | Completed 5, Terminated 4, Withdrawn 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Morphotek: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM) Placebo, Amatuximab, Pemetrexed - Mesothelioma, Malignant | Phase 2 | Terminated | Morphotek | 124 | 2015-11-03 | 2020-03-17 |
| MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Morphotek | 27 | 2013-11-01 | 2016-01-08 |
| Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC MORAb-066 - Breast Cancer, Pancreatic Cancer | Phase 1 | Completed | Morphotek | 27 | 2013-06-19 | 2024-03-29 |
| Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects MORAb-022 - Rheumatoid Arthritis | Phase 1 | Completed | Morphotek | 20 | 2013-05-01 | 2015-11-16 |
| Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation MORAb-004, Gemcitabine, Docetaxel - Metastatic Soft Tissue Sarcoma | Phase 2 | Completed | Morphotek | 209 | 2012-08-07 | 2019-08-21 |
| Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO) MORAb-004, Placebo, Best supportive care - Metastatic Colorectal Cancer, Colorectal Cancer | Phase 2 | Terminated | Morphotek | 154 | 2012-03-27 | 2022-05-06 |
| A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers Amatuximab - Mesothelioma, Pancreatic Cancer | Phase 1 | Completed | Morphotek | 6 | 2011-09-01 | 2016-09-30 |
| A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung Farletuzumab, Placebo, Carboplatin - Adenocarcinoma of the Lung | Phase 2 | Completed | Morphotek | 130 | 2011-06-27 | 2020-08-20 |
| Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas Farletuzumab - Resectable, Non-functioning Pituitary Adenoma | Phase 2 | Withdrawn | Morphotek | 2011-02-01 | 2013-11-04 | |
| A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma MORAb-028 - Metastatic Melanoma, Malignant Metastatic Melanoma | Phase 1 | Terminated | Morphotek | 18 | 2010-12-01 | 2014-07-16 |
| Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma MORAb028 - Melanoma | Phase 1 | Terminated | Morphotek | 18 | 2010-05-01 | 2014-07-17 |
| An Open Label Extension Study of the Efficacy of MORAb-003 MORAb-003 - Epithelial Ovarian Cancer | Phase 2 | Terminated | Morphotek | 3 | 2010-01-13 | 2021-12-08 |
| Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer Farletuzumab, Carboplatin, and PLD - Epithelial Ovarian Cancer | Phase 1 | Completed | Morphotek | 15 | 2009-11-01 | 2014-07-17 |
| Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse Farletuzumab, Carboplatin, Taxane - Ovarian Cancer | Phase 3 | Terminated | Morphotek | 1100 | 2009-04-16 | 2022-12-30 |
| A Study of of MORAb-004 in Subjects With Solid Tumors MORAb-004 (monoclonal antibody to TEM1) - Solid Tumor | Phase 1 | Completed | Morphotek | 80 | 2009-03-01 | 2014-07-16 |
| An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma MORAb-009 (Amatuximab), Pemetrexed, Cisplatin - Malignant Pleural Mesothelioma | Phase 2 | Completed | Morphotek | 89 | 2008-12-31 | 2022-09-22 |
| An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer MORAb-003 (farletuzumab), 0.9% Saline, Paclitaxel - Ovarian Cancer | Phase 2 | Terminated | Morphotek | 415 | 2008-09-01 | 2017-03-30 |
| An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer MORAb-009, Placebo, Gemcitabine - Pancreatic Cancer | Phase 2 | Completed | Morphotek | 155 | 2007-12-01 | 2015-09-09 |
| A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer MORAb-009 - Pancreatic Cancer, Mesothelioma | Phase 1 | Completed | Morphotek | 24 | 2006-05-01 | 2014-07-17 |
| Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy Farletuzumab, Chemo Plus Far - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | Morphotek | 58 | 2006-05-01 | 2015-09-09 |
Showing 20 of 21. Sign in to see all of them.
Ovarian Neoplasms (6) · Pancreatic Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Ovarian Epithelial (3) · Colorectal Neoplasms (2) · Melanoma (2) · Mesothelioma (2) · Mesothelioma, Malignant (2) · Adenocarcinoma (1) · Adenocarcinoma of Lung (1) · Arthritis, Rheumatoid (1) · Breast Neoplasms (1) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Fallopian Tube Neoplasms (1)
farletuzumab (8) · amatuximab (5) · ontuxizumab (4) · Carboplatin (3) · Cisplatin (3) · Pemetrexed (3) · Gemcitabine (2) · Paclitaxel (2) · 1-dodecylpyridoxal (1) · Docetaxel (1) · Drug Therapy (1) · Saline Solution (1) · gimsilumab (1) · taxane (1)
United States (21) · Germany (7) · Australia (5) · Canada (5) · Netherlands (5) · Spain (5) · Belgium (4) · Italy (4) · France (3) · Poland (2) · Russia (2) · United Kingdom (2) · Argentina (1) · Austria (1) · Brazil (1)
Bruce Wallin, MD (3) · Susan Weil, MD (3) · Susan C. Weil, M.D. (2) · Alan J. Kivitz, MD, CPI (1) · Christina Coughlin, MD, PhD (1) · Chrysoula Pappa, MD (1) · Jason Konner, M.D. (1) · Jorge Carrasquillo, MD (1) · Lydie Hazan, MD (1) · Nelson Oyesiku, MD, PhD, FACS (1) · Raffit Hassan, MD (1) · Robin Norris (1) · William M Schnitz, MD (1)
PMID 23474348, PMID 29292843, PMID 31034598
2008 (2), 2009 (1), 2014 (1), U01CA097452 (1)